CN112028989A - Chlorogenic acid artificial antigen and preparation method and application thereof - Google Patents
Chlorogenic acid artificial antigen and preparation method and application thereof Download PDFInfo
- Publication number
- CN112028989A CN112028989A CN202010956230.0A CN202010956230A CN112028989A CN 112028989 A CN112028989 A CN 112028989A CN 202010956230 A CN202010956230 A CN 202010956230A CN 112028989 A CN112028989 A CN 112028989A
- Authority
- CN
- China
- Prior art keywords
- chlorogenic acid
- artificial antigen
- acid
- preparing
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a chlorogenic acid artificial antigen which is characterized by comprising the following structures:
the preparation method comprises the following steps:
Description
Technical Field
The invention belongs to the field of biological medical treatment, and particularly relates to a preparation method and application of an artificial antigen of chlorogenic acid.
Background
Chlorogenic acid (CGA) has molecular weight of 354.31, CAS number of 327-97-9, and structural formula:
chlorogenic acid is depside generated from Caffeic acid (Caffeic acid) and Quinic acid (Quinic 1-hydroxyhexahydro gallic acid), is a phenylpropanoid compound generated by plants in the aerobic respiration process, widely exists in plants of the families of eucommia, Caprifoliaceae and Compositae, is an important bioactive substance, and has the effects of resisting bacteria, resisting viruses, increasing leukocyte, protecting liver, benefiting gallbladder, resisting tumors, reducing blood pressure, reducing blood fat, eliminating free radicals, exciting central nervous system and the like. The research on the biological activity of chlorogenic acid by modern science is deeply carried out in a plurality of fields of food, health care, medicine, daily chemical industry and the like. Therefore, the search for a suitable method for measuring the content of chlorogenic acid becomes an important link for the research of the traditional Chinese medicinal materials.
At present, the detection methods of chlorogenic acid at home and abroad mainly comprise: ultraviolet spectrophotometry, high performance liquid chromatography, gas chromatography, etc. These conventional instrumental analysis methods have the advantages of accurate, stable and reliable detection results, but require expensive instruments, complex operations and complex sample pretreatment, and are not suitable for rapid detection of a large number of samples. The immunoassay method has the advantages of simplicity, convenience, rapidness, sensitivity, good specificity and the like, and has important significance for detecting chlorogenic acid. In order to establish a rapid immunoassay method for chlorogenic acid, a chlorogenic acid artificial antigen and a preparation method thereof are needed to be provided.
CN105237633 discloses a chlorogenic acid complete antigen and a preparation method and application thereof, but the antiserum titer of the prepared antigen after immunizing animals needs to be improved, and the sensitivity for immunodetection is unknown.
Therefore, the application develops a novel chlorogenic acid artificial antigen and a preparation method thereof, the preparation method is simple and convenient in process, and immune animals can generate high-titer antibodies, so that the chlorogenic acid artificial antigen can be used for quickly detecting chlorogenic acid, and the detection sensitivity of the chlorogenic acid is improved.
Disclosure of Invention
The technical problem to be solved by the invention is to provide the chlorogenic acid artificial antigen which has high sensitivity and simple preparation method and can be used for quickly detecting the chlorogenic acid, and the preparation method and the application thereof.
In order to achieve the above purpose, the present invention provides the following technical solutions:
a chlorogenic acid artificial antigen has the following structure:
a method for artificial antigen synthesis of chlorogenic acid, comprising the steps of:
(1) weighing 30mg of bovine serum albumin or ovalbumin and 6mg of 6-aminocaproic acid, adding 8mL of 2- (N-morpholine) ethanesulfonic acid (MES) solution for dissolving, adding 25mg of EDAC, and continuously stirring at room temperature for reacting for 12 h;
(2) after the reaction is finished, putting the reaction solution into a dialysis bag, and dialyzing for 72 hours at 4 ℃ by PBS to obtain an aminated carrier protein solution;
(3) weighing chlorogenic acid 10mg, adding DMF to dissolve for 0.5mL, adding NHS 15mg and EDAC 16mg, stirring overnight at 16 deg.C, and stirring for 12 hr to obtain chlorogenic acid activated intermediate;
(4) on the next day, dropwise adding the chlorogenic acid activation intermediate product into the aminated carrier protein solution while stirring on a magnetic stirrer, and stirring overnight for reaction, namely continuously stirring for 12 hours;
(5) the next day, the overnight stirred reaction solution was placed in a treated dialysis bag and dialyzed in 0.01M PBS (pH 7.4) at 4 ℃ in a refrigerator for 72 hours, with the dialysate changed every 8 hours;
(6) and after the dialysis is finished, centrifuging the liquid in the dialysis bag, and removing precipitates to obtain the chlorogenic acid artificial antigen.
A method for preparing a chlorogenic acid antibody by using a chlorogenic acid artificial antigen, comprising the following steps:
(1) synthesizing artificial antigen of chlorogenic acid, wherein the immune antigen is synthesized by adopting chlorogenic acid and bovine serum albumin, and the detection antigen is synthesized by adopting chlorogenic acid and ovalbumin, namely the artificial antigen of chlorogenic acid is prepared by the method;
(2) selecting a healthy female mouse or a female Leiheng chicken as an experimental object, injecting the immune antigen, collecting eggs produced by the poultry or carrying out cell fusion by using mouse spleen cells to obtain hybridoma cells, and further obtaining a monoclonal antibody (Zhulixin, establishing an immunoaffinity column and detecting Sudan red I [ D ]. Nanchang university, 2011.);
(3) the IgG in the ascites of mice and the IgY in the eggs are purified by an octanoic acid-ammonium sulfate method (Shushuzhu, xuyang, Dunhong, et al. preparation of monoclonal antibody immunoaffinity column of ochratoxin A [ J ]. food science, 2009(09):172-175.) or a protein M affinity Chromatography method (Jiang X, Thiumalai D, Zhang X. affinity purification of egg immunoglobulin (IgY) using a human mycoplasmal protein of Chromatography B,2016, s 1012-1013: 37-41.); the IgG and IgY are antibodies to chlorogenic acid.
The method for preparing the immune egg comprises the following steps: the first immunization injection is carried out on 20-week-old poultry, the immunization dose is 350 mug/mouse, and after 21 days of the first immunization, 4 times of boosting immunization are carried out, the interval time is 21 days, and the immunization dose is 300 mug/mouse.
It is further described that the antigen is administered to the mice by injecting the first immunization into 6-8 week-old female mice at an immunization dose of 60. mu.g/mouse, and 21 days after the first immunization, 3 boosts are administered at an interval of 21 days at an immunization dose of 50. mu.g/mouse, and a fourth booster at an immunization dose of 30. mu.g/mouse.
The invention has the beneficial effects that the antibody can be effectively enhanced, specifically, the anti-chlorogenic acid IgY starts to generate the antibody about 20 days after the initial immunization, and the antibody titer reaches the highest about 90 days after the initial immunization, namely 1:256000, the antibody titer remained for more than one month after the cessation of the boost.
Compared with the prior art, the chlorogenic acid antigen developed by the invention has higher immunogenicity, the generated antibody has high specificity and sensitivity, the detection effect is good, and the method for preparing the antigen has simple steps and is simple and convenient.
Drawings
FIG. 1 is a reaction equation for synthesizing artificial antigen of chlorogenic acid according to the present invention;
FIG. 2 is a UV spectrum of chlorogenic acid artificial antigen;
FIG. 3 is SDS-PAGE of IgG antibody against chlorogenic acid purified by octanoic acid-ammonium sulfate method;
FIG. 4 is a SDS-PAGE electrophoresis of purified anti-chlorogenic acid IgG antibody;
FIG. 5 is a competition plot of chlorogenic acid.
FIG. 6 is a structural formula of chlorogenic acid artificial antigen.
Detailed Description
Preferred embodiments of the present invention are described in detail below.
Example 1: the invention relates to a method for preparing chlorogenic acid artificial antigen, which comprises the following steps:
(1) weighing 30mg of bovine serum albumin or ovalbumin and 6mg of 6-aminocaproic acid, adding 8mL of 0.01M MES solution for dissolving, adding 25mg of EDAC, and stirring at 25 ℃ for reaction for 12 h;
(2) after the reaction was completed, the reaction solution was placed in a dialysis bag (Mw <8000- > 14000) and dialyzed against 0.01M PBS (pH 7.4) at 4 ℃ for 72 hours to obtain an aminated carrier protein solution;
(3) weighing 10mg of chlorogenic acid, adding DMF0.5mL for dissolving, adding 15mg of NHS and 16mg of EDAC, stirring overnight at 16 ℃, continuously stirring for 12h, centrifuging the reaction solution at 6000r/min for 10min, removing precipitate, and preparing a chlorogenic acid activation intermediate product;
(4) on the next day, dropwise adding the chlorogenic acid activation intermediate product into the aminated carrier protein solution while stirring on a magnetic stirrer, stirring overnight for reaction, and continuously stirring for 12 h;
(5) the next day, the overnight stirred reaction solution was placed in a treated dialysis bag and dialyzed in 0.01M PBS (pH 7.4) at 4 ℃ in a refrigerator for 72h, with the dialysate changed every 8 h;
(6) and after the dialysis is finished, centrifuging the liquid in the dialysis bag, and removing precipitates to obtain the chlorogenic acid artificial antigen.
The specific reaction equation is shown in FIG. 1.
The embodiment of the invention respectively carries out ultraviolet scanning on chlorogenic acid, BSA and chlorogenic acid artificial antigen at 200-800 nm. FIG. 2 is the ultraviolet scan before and after the preparation of chlorogenic acid artificial antigen. As shown in figure 2, the ultraviolet absorption peak of the chlorogenic acid artificial antigen has a certain shift compared with BSA and chlorogenic acid, which indicates that the chlorogenic acid and the carrier protein are successfully coupled, and the chlorogenic acid artificial antigen is successfully prepared by the embodiment of the invention.
Further, a method of preparing chlorogenic acid antibodies, comprising the steps of:
(1) preparing chlorogenic acid artificial antigen, wherein the immune antigen is synthesized by adopting chlorogenic acid and bovine serum albumin, and the detection antigen is synthesized by adopting chlorogenic acid and ovalbumin;
(2) selecting a healthy female mouse or a female Leiheng chicken as an experimental object, injecting the immune antigen, collecting eggs produced by the poultry or carrying out cell fusion by using mouse spleen cells to obtain hybridoma cells, and further obtaining a monoclonal antibody (Zhulixin, establishing an immunoaffinity column and detecting Sudan red I [ D ]. Nanchang university, 2011.);
(3) purifying by caprylic acid-ammonium sulfate method or protein M affinity chromatography to obtain IgG in mouse ascites and IgY in egg; the IgG and IgY are antibodies to chlorogenic acid.
The method for preparing the immune egg comprises the following steps: the method comprises the steps of carrying out primary immunization injection on 20-week-old poultry, wherein the immunization dose is 350 mu g/poultry, carrying out secondary immunization 21 days after the primary immunization, wherein the immunization dose is 300 mu g, carrying out tertiary immunization 42 days after the secondary immunization, wherein the immunization dose is 300 mu g, carrying out quartic immunization 63 days after the tertiary immunization, wherein the immunization dose is 300 mu g, carrying out quintic immunization 84 days after the quartic immunization, and wherein the immunization dose is 300 mu g.
Further, the method for immunizing the mice by the antigen comprises the following steps of carrying out primary immunization injection on 6-8 week-old female balb/c mice, wherein the immunization dose is 60 mu g/mouse, carrying out secondary immunization 21 days after the primary immunization, the immunization dose is 50 mu g, carrying out three times of immunization 42 days after the secondary immunization, the immunization dose is 50 mu g, carrying out four times of immunization 63 days after the three times of immunization, the immunization dose is 50 mu g, carrying out five times of immunization 84 days after the four times of immunization, and the immunization dose is 30 mu g.
As shown in fig. 2 to 5, for further explanation, the titer of chlorogenic acid antibody was measured:
(1) coating an enzyme label plate: preparing 2 mu g/mL chlorogenic acid-ovalbumin solution by using CBS solution, adding a 96-well enzyme label plate into 100 mu L/well, incubating overnight at 37 ℃, removing liquid in the well, and washing the plate for 4 times by using PBST;
(2) and (3) sealing: blocking the wells with 2% BSA, incubating at 37 ℃ for 2h, discarding the liquid in the wells, and washing the plates with PBST 4 times;
(3) addition of purified IgY or IgG: adding 100 mu L of PBS for bedding every hole, taking out the IgY solution obtained by separation and purification, recovering to room temperature, diluting with a diluent PBS1: 1000, adding 100 mu L into the first hole, sucking 100 mu L after blowing, sucking and uniformly mixing, adding into the second hole, and sequentially diluting to 1:256000 in a multiple ratio. Extracting antibody 100 μ L from blank egg or mouse serum as Negative Control (NC), PBS 100 μ L as Blank Control (BC), incubating at 37 deg.C for 40min, discarding liquid in the well, and washing plate;
(4) adding an enzyme-labeled secondary antibody: diluting goat anti-chicken IgY or rabbit anti-mouse IgG labeled by horseradish peroxidase with PBS1:5000, adding 100 mu L per hole, incubating at 37 ℃ for 40min, discarding liquid in the hole, and washing the plate;
(5) color development: adding freshly prepared TMB-H2O2Placing 100 mu L of substrate liquid in each hole at room temperature in a dark place for 8-10 minutes, removing liquid in the holes, and washing the plate;
(6) and (4) terminating: finally, 50. mu.L of 2M H was added2SO4Stopping reaction, measuring the OD value of the reaction product by using an enzyme-linked immunosorbent assay at the wavelength of 450nm, and repeating the step three times for each hole to obtain an average value;
(7) and (4) judging a result: determining OD of sample well450Value (P) and negative control well OD450When the P/N ratio of the value (N) is more than or equal to 2.1, the antibody is judged to be positive, and the maximum dilution multiple of the corresponding antibody is the titer of the antibody.
The results show that the anti-chlorogenic acid-IgY starts to produce the antibody about 20 days after the priming, and the antibody titer reaches the highest value about 90 days after the priming, namely 1:256000, the antibody titer remained for more than one month after the cessation of the boost. The titer of anti-chlorogenic acid-IgG reaches 1: 640000.
The invention also detects the purity of the antibody of the antigen immunized animal prepared in the example 1, and the method comprises the following steps: preparing 5% concentrated gel and 12% separation gel, diluting the prepared purified antibody to 1mg/Ml, adjusting the voltage of the concentrated gel to 90V and the voltage of the separation gel to 120V, performing polyacrylamide gel electrophoresis (SDS-PAGE), dyeing with Coomassie brilliant blue, and scanning an electrophoresis pattern after decoloring. FIG. 3 is an SDS-PAGE picture of purified chlorogenic acid IgG, which shows clear staining band and high aggregation degree, and indicates that the purity of the produced chlorogenic acid antibody is high.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (6)
1. A chlorogenic acid artificial antigen is characterized by having the following structure:
2. use of the artificial antigen of chlorogenic acid as claimed in claim 1 in the preparation of a kit for detecting chlorogenic acid.
3. A method for preparing chlorogenic acid artificial antigen according to claim 1, characterized by comprising the following steps:
(1) weighing carrier protein and 6-aminocaproic acid, adding 2- (N-morpholine) ethanesulfonic acid (MES) solution for dissolving, adding carbodiimide hydrochloride (EDAC), and continuously stirring for reacting for 12h at room temperature;
(2) after the reaction is finished, putting the reaction solution into a dialysis bag, and dialyzing for 72 hours at 4 ℃ by PBS to obtain an aminated carrier protein solution;
(3) weighing chlorogenic acid, adding DMF to dissolve, adding NHS and EDAC, stirring at 16 deg.C overnight to obtain chlorogenic acid activated intermediate;
(4) dropwise adding the chlorogenic acid activation intermediate product into the aminated carrier protein solution while stirring on a magnetic stirrer, and stirring overnight;
(5) the next day, the overnight stirred reaction solution was placed in a treated dialysis bag and dialyzed in 0.01M PBS at 4 ℃ for 72h, and the dialysate was changed every 8 h;
(6) and after the dialysis is finished, centrifuging the liquid in the dialysis bag, and removing precipitates to obtain the chlorogenic acid artificial antigen.
4. The method for preparing an artificial antigen of chlorogenic acid according to claim 3, characterized in that: in the step (1), 30mg of bovine serum albumin or ovalbumin is used as the carrier protein; 6mg of 6-aminocaproic acid; 8mL of 2- (N-morpholine) ethanesulfonic acid (MES) solution, 25mg of EDAC.
5. The method for preparing an artificial antigen of chlorogenic acid according to claim 3, characterized in that: in the step (3), the chlorogenic acid is 10 mg; DMF0.5 mL; NHS 15 mg; EDAC was 16 mg.
6. The method for preparing an artificial antigen of chlorogenic acid according to claim 3, characterized in that: the pH of PBS was 7.4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010956230.0A CN112028989B (en) | 2020-09-11 | 2020-09-11 | Chlorogenic acid artificial antigen and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010956230.0A CN112028989B (en) | 2020-09-11 | 2020-09-11 | Chlorogenic acid artificial antigen and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112028989A true CN112028989A (en) | 2020-12-04 |
| CN112028989B CN112028989B (en) | 2022-12-02 |
Family
ID=73588971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010956230.0A Active CN112028989B (en) | 2020-09-11 | 2020-09-11 | Chlorogenic acid artificial antigen and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112028989B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113475620A (en) * | 2021-07-19 | 2021-10-08 | 中国海洋大学 | Zein-polyphenol covalent compound and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101486762A (en) * | 2008-01-18 | 2009-07-22 | 北京中医药大学 | Antibody, method and reagent kit for detecting and determining chlorogenic acid |
| CN105237633A (en) * | 2015-10-15 | 2016-01-13 | 深圳市药品检验所 | Chlorogenic acid complete antigen, preparation method and application thereof |
| EP2987802A1 (en) * | 2014-08-22 | 2016-02-24 | Stern Enzym GmbH & Co. KG | An enzyme with chlorogenic acid esterase activity and feruloyl esterase activity |
-
2020
- 2020-09-11 CN CN202010956230.0A patent/CN112028989B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101486762A (en) * | 2008-01-18 | 2009-07-22 | 北京中医药大学 | Antibody, method and reagent kit for detecting and determining chlorogenic acid |
| EP2987802A1 (en) * | 2014-08-22 | 2016-02-24 | Stern Enzym GmbH & Co. KG | An enzyme with chlorogenic acid esterase activity and feruloyl esterase activity |
| CN105237633A (en) * | 2015-10-15 | 2016-01-13 | 深圳市药品检验所 | Chlorogenic acid complete antigen, preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| JIYUN V KIM ET AL.: ""The ABCs of artificial antigen presentation"", 《NATURE BIOTECHNOLOGY》 * |
| 秦美蓉 等: ""活泼酯法合成绿原酸人工抗原及其鉴定"", 《沈阳药科大学学报》 * |
| 薛瑾 等: ""绿原酸人工抗原的合成及多克隆抗体的制备"", 《中草药》 * |
| 赵宁毅 等: ""中药小分子化合物人工抗原的制备及鉴定"", 《时珍国医国药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113475620A (en) * | 2021-07-19 | 2021-10-08 | 中国海洋大学 | Zein-polyphenol covalent compound and preparation method thereof |
| CN113475620B (en) * | 2021-07-19 | 2023-05-26 | 中国海洋大学 | Zein-polyphenol covalent complex and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112028989B (en) | 2022-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110845444B (en) | Dimethomorph hapten, artificial antigen and antibody, and preparation method and application thereof | |
| CN104119277B (en) | A kind of it is directed to the hapten of histamine, artificial antigen, antibody and preparation method and application | |
| CN106866568A (en) | Furaxone metabolite AOZ derivatizations haptens, the preparation method and applications of artificial antigen | |
| CN108558718B (en) | Florfenicol, florfenicol amine antigen and antibody and simultaneous detection enzyme-linked immunoassay method thereof | |
| CN109824599A (en) | A kind of albendazole haptens and its preparation method and application | |
| CN107012128B (en) | Hybridoma cell strain secreting monoclonal antibody against aflatoxin B1 and application thereof | |
| CN106831498B (en) | Furacilin metabolite SEM derivatizations haptens, artificial antigen preparation method and applications | |
| CN112028989B (en) | Chlorogenic acid artificial antigen and preparation method and application thereof | |
| CN109212200A (en) | A kind of Nicarbazin haptens, artificial antigen and the preparation method and application thereof | |
| CN110950962B (en) | Hybridoma cell strain A11S for secreting bimesomepheniul monoclonal antibody and application thereof | |
| CN114316027A (en) | Flunixin artificial antigen and preparation method and application thereof | |
| CN107118159A (en) | Cistofuran metabolite AHD derivatizations haptens, the preparation method and applications of artificial antigen | |
| CN114990072B (en) | Hybridoma cell strain secreting anti-quinolone antibiotic monoclonal antibody and application thereof | |
| CN114752568B (en) | Furosemide monoclonal antibody, hybridoma cell strain and application | |
| CN116120430A (en) | Folic acid complete antigen and antibody, and preparation method and application thereof | |
| CN113046325B (en) | Vitamin K 3 Monoclonal antibody hybridoma cell strain and application thereof | |
| CN110927376B (en) | Magnetic immunochemistry luminescence detection kit of olaquindox and application thereof | |
| CN109705220A (en) | One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application | |
| CN112939873B (en) | Trimethoprim hapten TMPH, artificial antigen, antibody and preparation method and application thereof | |
| CN110357886A (en) | Methotrexate (MTX) haptens and comlete antigen and its preparation method and application | |
| CN107083368B (en) | hybridoma cell strains secreting monoclonal antibodies against total aflatoxin and application thereof | |
| CN108107223A (en) | Detect method and its enzyme linked immunological kit used of estradiol and/or oestradiol benzoate | |
| CN107513522B (en) | Hybridoma cell strain secreting anti-ochratoxin monoclonal antibody and application thereof | |
| CN110616194A (en) | Aconitine monoclonal antibody cell strain SJ and application thereof | |
| CN105237633A (en) | Chlorogenic acid complete antigen, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |